Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

Core Insights - Myriad Genetics reported $213.3 million in revenue for the quarter ended September 2024, marking an 11.2% year-over-year increase and exceeding the Zacks Consensus Estimate of $209.82 million by 1.66% [1] - The company achieved an EPS of $0.06, a significant improvement from -$0.03 a year ago, resulting in a 200.00% EPS surprise compared to the consensus estimate of $0.02 [1] Revenue Breakdown by Product - Prenatal revenue reached $43.50 million, surpassing the average estimate of $42.99 million, with a year-over-year increase of 10.1% [3] - Hereditary Cancer revenue was $90.50 million, slightly above the $89.63 million average estimate, reflecting a 4.6% year-over-year change [3] - Pharmacogenomics revenue totaled $47.70 million, exceeding the estimated $40.60 million, showing a substantial year-over-year increase of 33.6% [3] - Tumor Profiling revenue was reported at $31.60 million, below the average estimate of $36.08 million, with a year-over-year increase of 4.6% [3] Stock Performance - Myriad's shares have declined by 27.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.2% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]